Loading company
Volitionrx Ltd.
VNRX · NYSE · ·
$0.25+2.0%Sep 29 close
- 1M
- -43.4%
- 6M
- -93.3%
- 1Y
- -98.1%
- 5Y
- -99.6%
VNRX · NYSE · ·
$0.25+2.0%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $398.7K | $406.7K | -1.97% |
| Profit | -$7.3M | -$6.3M | -16.58% |
| Profit per share | -$0.85 | -$1.12 | +24.11% |
| Free Cash Flow | -$5.2M | -$6.3M | +18.58% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Volitionrx Ltd. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life. Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. The contents found at Volition’s website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only. Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620 2
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Volitionrx Ltd.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.